GlassScriptPhysician profile
Sina Matin
NPI 1366481228
$9,742.91
in general payments reported to CMS, 2019-2025
13 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,324 · 2020: $1,589 · 2021: $247 · 2022: $1,596 · 2023: $794 · 2024: $1,170 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711 · Travel and Lodging: $234 · Gift: $43.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.72 |
| Travel and Lodging | $233.88 |
| Gift | $43.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,692.62 | 2019-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $1,094.51 | 2022-2025 | |
| Ethicon US, LLC | $359.88 | 2020-2024 | Stratafix, Proximate, Echelon Endopath |
| Covidien LP | $162.26 | 2019 | |
| W. L. Gore & Associates, INC. | $146.65 | 2022 | |
| Novo Nordisk INC | $92.76 | 2020-2025 | Wegovy |
| Allergan, INC. | $48.17 | 2022 | |
| Integra Lifesciences Corporation | $37.35 | 2021-2022 | |
| Vivus LLC | $29.68 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $27.48 | 2023 | Myrisk |
| Tei Biosciences INC | $20.50 | 2019 | |
| Bard Peripheral Vascular, INC. | $18.21 | 2019 | |
| Acell, INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sina Matin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.